Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-... Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-sized nanoparticles and have proprietary coatings. It has applied the AMPPLIFY technology to create nanosuspensions of loteprednol etabonate, or LE, acorticosteroid designed for ocular applications, resulting in two product candidates. INVELTYS was approved in August 2018 for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25 per cent is in Phase 3 development for the temporary relief of the signs and symptoms of dry eye disease. Show more
ARLINGTON, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
ARLINGTON, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results expected in 2Q 2025 -- -- Initiated five clinical trial sites for...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.88 | 12.4822695035 | 7.05 | 8.79 | 6.52 | 68063 | 7.43860478 | CS |
4 | 1.6 | 25.2764612954 | 6.33 | 8.79 | 5.67 | 35273 | 6.81552697 | CS |
12 | 2.68 | 51.0476190476 | 5.25 | 8.79 | 4.95 | 33573 | 6.78321671 | CS |
26 | 1.35 | 20.5167173252 | 6.58 | 8.79 | 4.95 | 27735 | 6.69742579 | CS |
52 | 0.93 | 13.2857142857 | 7 | 9.25 | 4.21 | 73907 | 6.61400205 | CS |
156 | -53.57 | -87.1056910569 | 61.5 | 97 | 3.5444 | 736047 | 30.42514932 | CS |
260 | -186.57 | -95.9228791774 | 194.5 | 734 | 3.5444 | 1070200 | 205.86293399 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales